Study wrapper · #513
Metabolic dysfunction-associated steatotic liver disease in people with HIV.
Editor's note
This is a clinical review of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV, in which tesamorelin (a GHRH analog) and GLP-1 receptor agonists are highlighted as therapies showing promise in this specific population. As a narrative review it frames the evidence rather than adding new data. The relevant point for our readers: liver disease in HIV follows a more aggressive course and HIV-specific factors alter its biology, so treatments studied in the general population need dedicated evaluation in HIV — and tesamorelin is among the agents with encouraging HIV-specific data. Read it as an authoritative overview of where tesamorelin fits in the MASLD-HIV treatment landscape, not as trial-level efficacy evidence.
Plain-language abstract
This review examines fatty liver disease — now called MASLD — in people living with HIV, where it is common and tends to progress faster than in HIV-negative people. The authors explain that while the underlying biology overlaps with fatty liver in the general population, HIV-specific factors such as altered body fat, chronic immune activation, gut changes, and antiretroviral drugs can speed the disease along. They note a gap: most new liver-disease treatments have not been tested specifically in people with HIV. Two exceptions with encouraging early data are GLP-1 receptor agonists and tesamorelin, a growth-hormone-releasing hormone analog. Because this is a summary of existing knowledge rather than a new experiment, it is best used to understand how tesamorelin fits into the broader picture of managing fatty liver in HIV.